Product Description
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that functionally antagonises activity of the glucagon receptor (GCGR) in vitro (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9614)
Mechanisms of Action: GcGr Blocker
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Regeneron
Company Location: Eastern America
Company CEO: Leonard S. Schleifer
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02284425 |
R1193-DM-1402 | P1 |
Terminated |
Type 2 Diabetes |
2015-12-01 |
2019-03-20 |
Treatments |
|
NCT01933763 |
R1193-HV-1219 | P1 |
Completed |
Healthy Volunteers |
2015-01-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|